"Our strategy of introducing new products includes expanding the new technology platform developed for SolarisPlus, which will allow additional new products to be developed quickly and inexpensively," added Cullimore.
"In addition, other technologies and products are being developed which will complement our popular line of therapy device products. We believe this strategy will enhance our growth potential and help us reach our performance goals for fiscal years 2013 and 2014."
Dynatronics has scheduled a conference call for investors on Wednesday, February 13, 2013, at 3:00 p.m. ET. Those wishing to participate should call (800) 616-4707.
The following is a summary of the financial results as of December 31, 2012 and 2011, and for the three- and six-month periods then ended:Summary Selected Financial DataStatement of Operations HighlightsThree Months Ended Six Months Ended December 31,December 31,2012201120122011Net sales
16,272,232Cost of sales 4,899,4045,062,4729,394,58210,057,176Gross profit 3,098,9153,212,9585,809,7636,215,056SG&A expenses 2,565,2822,686,4015,024,3865,381,268R&D expenses 274,379412,861540,646769,208Other expenses, net 59,11141,517118,19698,330Net income (loss) before income
tax (benefit) provision200,14372,179126,535(33,750)Income tax benefit (provision) (59,160)(25,845)(36,696)11,824Net income (loss)
|SOURCE Dynatronics Corporation|
Copyright©2012 PR Newswire.
All rights reserved